Impact of the Technology: This agent (a biogeneric) has previously shown, promise as an improved clot-buster in clinical trials abroad. Summary of the work: A recombinant strain has been developed for high level intracellular production of Staphylokinase in E. coli. A high-efficiency facile two step protocol for purification of staphylokinase has also been developed. The complete technological package for the production for recombinant staphylokinase has been transferred to M/S Strides Arcolab Ltd., Bangalore. Commercialization status: The licensee is working on development of the commercial scale process with IMTECH’s advice at the pre-clinical testing stage.